Reuters logo
BRIEF-GlaxoSmithKline gives update on Albiglutide study
June 24, 2013 / 9:12 AM / 4 years ago

BRIEF-GlaxoSmithKline gives update on Albiglutide study

LONDON, June 24 (Reuters) - GlaxoSmithKline Plc : * Albiglutide combination therapy demonstrated statistically significant

reduction in hba1c from baseline compared to placebo * Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below